AMEX · NBY
NovaBay Pharmaceuticals, Inc.
$1.47-$0.48 (-24.62%)
NovaBay Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.53% below the high.
Loading market information…
NASDAQ · ADXN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Addex Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 71.91% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Addex Therapeutics Ltd’s next earnings report is currently expected on Nov 9, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Addex Therapeutics Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:03 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| Apr 7, 2025 |
| -$1.63-14.71% vs estimate |
| $1.66K-98.89% vs estimate |
| Q3 2024 | Nov 22, 2024 | -$2.77-97.86% vs estimate | $62.72K-58.18% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.47-$0.48 (-24.62%)
NovaBay Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.53% below the high.
$3.99+$0.00 (0.0%)
Impact BioMedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.02% below the high.
$5.05+$1.34 (+36.12%)
Adial Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.41% below the high.
$0.91+$0.11 (+13.78%)
Brainstorm Cell Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.15% below the high.
$4.15+$0.04 (+0.97%)
Quoin Pharmaceuticals, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 82.34% below the high.
$1.89-$0.24 (-11.27%)
Alaunos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.0% below the high.
$1.75+$0.05 (+2.94%)
Cardio Diagnostics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.88% below the high.
$2.13-$0.23 (-9.75%)
NeuroSense Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 91.61% below the high.
